High-relaxivity contrast-enhanced magnetic resonance neuroimaging: A review

European Radiology

Volumn 20, Issue 10, 2010, Pages 2461-2474

  Giesel, Frederik L ^a,b   Mehndiratta, Amit ^a,c   Essig, Marco ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Contrast media; Magnetic resonance imaging; Neuroimaging; Protein affinity; Relaxivity

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID;

BRAIN DAMAGE; BRAIN TUMOR; CEREBROVASCULAR DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEMODYNAMICS; HUMAN; IMAGE QUALITY; MAGNETIC FIELD; MAGNETIC RESONANCE ANGIOGRAPHY; MULTIPLE SCLEROSIS; NEUROIMAGING; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; STROKE;

BRAIN; BRAIN MAPPING; BRAIN NEOPLASMS; CONTRAST MEDIA; GADOLINIUM DTPA; HEMODYNAMICS; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MEGLUMINE; MODELS, NEUROLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; STROKE;

EID: 77957880675     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-010-1805-8     Document Type: Review

References (79)

1. FM Cavagna F Maggioni PM Castelli M Dapra LG Imperatori V Lorusso BG Jenkins 1997 Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging Invest Radiol 32 780 796 10.1097/00004424-199712000-00009 9406019 1:CAS:528:DyaK2sXnvFGhur4%3D (Pubitemid 28053510)
2. FL Giesel H von Tengg-Kobligk ID Wilkinson P Siegler CW von der Lieth M Frank KP Lodemann M Essig 2006 Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents Invest Radiol 41 222 228 10.1097/01.rli.0000192421.81037.d5 16481904 1:CAS:528:DC%2BD28XhsVKqtrw%3D (Pubitemid 44406182)
3. C de Haen M Cabrini L Akhnana D Ratti L Calabi L Gozzini 1999 Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium J Comput Assist Tomogr 23 Suppl 1 S161 S168 10608412
4. J Pintaske P Martirosian H Graf G Erb KP Lodemann CD Claussen F Schick 2006 Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla Invest Radiol 41 213 221 10.1097/01.rli.0000197668.44926.f7 16481903 (Pubitemid 44406181)
5. M Rohrer H Bauer J Mintorovitch M Requardt HJ Weinmann 2005 Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths Invest Radiol 40 715 724 10.1097/01.rli.0000184756.66360.d3 16230904 (Pubitemid 41546838)
6. M Goyen 2008 Gadofosveset-enhanced magnetic resonance angiography Vasc Health Risk Manag 4 1 9 10.2147/vhrm.2008.04.01.1 18629367 1:CAS:528: DC%2BD1cXkslKqu78%3D (Pubitemid 351460842)
7. CJ Zech KA Herrmann MF Reiser SO Schoenberg 2007 MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA Magn Reson Med Sci 6 43 52 10.2463/mrms.6.43 17510541
8. AG Bleicher E Kanal 2008 A serial dilution study of gadolinium-based MR imaging contrast agents AJNR Am J Neuroradiol 29 668 673 10.3174/ajnr.A0905 18184840 1:STN:280:DC%2BD1c3js1Krsw%3D%3D (Pubitemid 351571544)
9. WT Yuh JD Engelken MG Muhonen NA Mayr DJ Fisher JC Ehrhardt 1992 Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases AJNR Am J Neuroradiol 13 335 345 1595472 1:STN:280: DyaK383otVGhug%3D%3D
10. WT Yuh DJ Fisher JD Engelken GM Greene Y Sato TJ Ryals MR Crain JC Ehrhardt 1991 MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol Radiology 180 485 491 2068317 1:STN:280:DyaK3M3pslSqsA%3D%3D
11. J Haustein M Laniado HP Niendorf T Louton W Beck J Planitzer M Schoffel M Reiser W Kaiser W Schorner 1993 Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients Radiology 186 855 860 8430199 1:STN:280:DyaK3s7lslKjsQ%3D%3D
12. WT Yuh DJ Fisher VM Runge SW Atlas SE Harms KR Maravilla NA Mayr JE Mollman AC Price 1994 Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases AJNR Am J Neuroradiol 15 1037 1051 8073972 1:STN:280:DyaK2czlsVSntw%3D%3D
13. VM Runge JE Kirsch VJ Burke AC Price KL Nelson GS Thomas BL Dean C Lee 1992 High-dose gadoteridol in MR imaging of intracranial neoplasms J Magn Reson Imaging 2 9 18 10.1002/jmri.1880020103 1623287 1:STN:280:DyaK38zitlWrsA%3D%3D
14. G Sze C Johnson Y Kawamura SN Goldberg R Lange RJ Friedland RJ Wolf 1998 Comparison of single-and triple-dose contrast material in the MR screening of brain metastases AJNR Am J Neuroradiol 19 821 828 9613494 1:STN:280: DyaK1c3ntlGmsg%3D%3D
15. G Schneider MA Kirchin G Pirovano C Colosimo J Ruscalleda M Korves I Salerio NA La A Spinazzi 2001 Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation J Magn Reson Imaging 14 525 539 10.1002/jmri.1216 11747004 1:STN:280:DC%2BD3MnpsFylsQ%3D%3D (Pubitemid 33029538)
16. DR Broome MS Girguis PW Baron AC Cottrell I Kjellin GA Kirk 2007 Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned AJR Am J Roentgenol 188 586 592 10.2214/AJR.06.1094 17242272 (Pubitemid 46167763)
17. EA Sadowski LK Bennett MR Chan AL Wentland AL Garrett RW Garrett A Djamali 2007 Nephrogenic systemic fibrosis: risk factors and incidence estimation Radiology 243 148 157 10.1148/radiol.2431062144 17267695 (Pubitemid 46579705)
18. E Kanal DR Broome DR Martin HS Thomsen 2008 Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update Radiology 246 11 14 10.1148/radiol.2461071267 17855656 (Pubitemid 350305022)
19. D Baleriaux C Colosimo J Ruscalleda M Korves G Schneider K Bohndorf G Bongartz MA van Buchem M Reiser K Sartor MW Bourne PM Parizel GR Cherryman I Salerio NA La G Pirovano MA Kirchin A Spinazzi 2002 Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine Neuroradiology 44 191 203 10.1007/s002340100636 11942372 1:STN:280:DC%2BD383gvVagsQ%3D%3D (Pubitemid 36075908)
20. C Colosimo J Ruscalleda M Korves FR La C Wool P Pianezzola MA Kirchin 2001 Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage Invest Radiol 36 72 81 10.1097/00004424-200102000-00002 11224754 1:STN:280:DC%2BD3M3hsVSkuw%3D%3D (Pubitemid 32147853)
21. MV Knopp VM Runge M Essig M Hartman O Jansen MA Kirchin A Moeller AH Seeberg KP Lodemann 2004 Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine Radiology 230 55 64 10.1148/radiol.2301021085 14695387 (Pubitemid 37549783)
22. C Colosimo MV Knopp X Barreau E Gerardin MA Kirchin F Guezenoc KP Lodemann 2004 A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours Neuroradiology 46 655 665 10.1007/s00234-003-1128-4 15205859 1:STN:280:DC%2BD2cvgsFSktg%3D%3D
23. KR Maravilla JA Maldjian IM Schmalfuss MJ Kuhn BC Bowen FJ Wippold VM Runge MV Knopp S Kremer LJ Wolansky N Anzalone M Essig L Gustafsson 2006 Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents Radiology 240 389 400 10.1148/radiol.2402051266 16801373 (Pubitemid 44098634)
24. MJ Kuhn P Picozzi JA Maldjian IM Schmalfuss KR Maravilla BC Bowen FJ Wippold VM Runge MV Knopp LJ Wolansky L Gustafsson M Essig N Anzalone 2007 Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention J Neurosurg 106 557 566 10.3171/jns.2007.106.4.557 17432704 1:CAS:528:DC%2BD2sXksFKjtbg%3D
25. Z Rumboldt HA Rowley F Steinberg JA Maldjian J Ruscalleda L Gustafsson S Bastianello 2009 Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 Tesla J Magn Reson Imaging 29 760 767 10.1002/jmri.21695 19306364
26. HA Rowley G Scialfa PY Gao JA Maldjian D Hassell MJ Kuhn FJ Wippold M Gallucci BC Bowen IM Schmalfuss J Ruscalleda S Bastianello C Colosimo 2008 Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide AJNR Am J Neuroradiol 29 1684 1691 10.3174/ajnr.A1185 18599575 1:STN:280: DC%2BD1cnkvVCksQ%3D%3D
27. M Goyen M Edelman P Perreault E O'Riordan H Bertoni J Taylor D Siragusa M Sharafuddin ER Mohler III R Breger EK Yucel K Shamsi RM Weisskoff 2005 MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325 Radiology 236 825 833 10.1148/radiol.2363040577 16020554 (Pubitemid 41170843)
28. JH Rapp SD Wolff SF Quinn JA Soto SG Meranze S Muluk J Blebea SP Johnson NM Rofsky A Duerinckx GS Foster KC Kent G Moneta MR Middlebrook VR Narra BD Toombs J Pollak EK Yucel K Shamsi RM Weisskoff 2005 Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography-multicenter comparative phase III study Radiology 236 71 78 10.1148/radiol.2361040148 15987963 (Pubitemid 40853296)
29. M Essig A Tartaro T Tartaglione G Pirovano MA Kirchin A Spinazzi 2006 Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators Acad Radiol 13 744 751 10.1016/j.acra.2006.02.056 16679277
30. P Picozzi MA Kirchin 2007 Improving lesion detection and visualization: implications for neurosurgical planning and follow-up Neuroradiology 49 Suppl 1 S27 S34 10.1007/s00234-007-1470-4 17665155 (Pubitemid 47193854)
31. A Villringer BR Rosen JW Belliveau JL Ackerman RB Lauffer RB Buxton YS Chao VJ Wedeen TJ Brady 1988 Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects Magn Reson Med 6 164 174 10.1002/mrm.1910060205 3367774 1:STN:280:DyaL1c3hs1Srsg%3D%3D
32. M Essig MA Weber H von Tengg-Kobligk MV Knopp WT Yuh FL Giesel 2006 Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications Top Magn Reson Imaging 17 89 106 10.1097/01.rmr.0000245464.36148.dc 17198225 (Pubitemid 46050572)
33. L Ostergaard AG Sorensen KK Kwong RM Weisskoff C Gyldensted BR Rosen 1996 High resolution measurement of cerebral blood flow using intravascular tracer bolus passages Part II: Experimental comparison and preliminary results. Magn Reson Med 36 726 736 1:STN:280:DyaK2s%2Fntlaktw%3D%3D
34. M Fuss F Wenz R Scholdei M Essig J Debus MV Knopp M Wannenmacher 2000 Radiation-induced regional cerebral blood volume (rCBV) changes in normal brain and low-grade astrocytomas: quantification and time and dose-dependent occurrence Int J Radiat Oncol Biol Phys 48 53 58 10.1016/S0360-3016(00)00590-3 10924971 1:STN:280:DC%2BD3czps1aqsg%3D%3D (Pubitemid 30488212)
35. M Essig KP Lodemann M Le-Huu R Bruning M Kirchin W Reith 2006 Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T Invest Radiol 41 256 263 10.1097/01.rli.0000191333.19068.6b 16481908 1:CAS:528:DC%2BD28XhsVKqtrs%3D (Pubitemid 44406186)
36. EA Knopp S Cha G Johnson A Mazumdar JG Golfinos D Zagzag DC Miller PJ Kelly II Kricheff 1999 Glial neoplasms: dynamic contrast-enhanced T2-weighted MR imaging Radiology 211 791 798 10352608 1:STN:280:DyaK1M3otVyktg%3D%3D
37. L Rizzo SG Crasto PG Moruno P Cassoni R Ruda R Boccaletti M Brosio LR De C Fava 2009 Role of diffusion-and perfusion-weighted MR imaging for brain tumour characterisation Radiol Med 114 645 659 10.1007/s11547-009-0401-y 19430732 1:STN:280:DC%2BD1MrmsVOiug%3D%3D
38. S Cha EA Knopp G Johnson SG Wetzel AW Litt D Zagzag 2002 Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging Radiology 223 11 29 10.1148/radiol.2231010594 11930044
39. F Cotton M Hermier 2006 The advantage of high relaxivity contrast agents in brain perfusion Eur Radiol 16 Suppl 7 M16 M26 18655263
40. N Rollin J Guyotat N Streichenberger J Honnorat M Tran Minh F Cotton 2006 Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intra-axial brain tumors Neuroradiology 48 150 159 10.1007/s00234-005-0030-7 16470375 1:STN:280:DC%2BD287ktlelsw%3D%3D (Pubitemid 43380227)
41. B Tombach T Benner P Reimer G Schuierer EM Fallenberg V Geens T Wels AG Sorensen 2003 Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/l gadobutrol Radiology 226 880 888 10.1148/radiol.2263011970 12601217 (Pubitemid 36259167)
42. BR Rosen JW Belliveau D Chien 1989 Perfusion imaging by nuclear magnetic resonance Magn Reson Q 5 263 281 2701285 1:STN:280:DyaK3czksVKjtQ%3D%3D
43. BR Rosen JW Belliveau JM Vevea TJ Brady 1990 Perfusion imaging with NMR contrast agents Magn Reson Med 14 249 265 10.1002/mrm.1910140211 2345506 1:STN:280:DyaK3c3msFamsQ%3D%3D (Pubitemid 20248610)
44. JL Boxerman LM Hamberg BR Rosen RM Weisskoff 1995 MR contrast due to intravascular magnetic susceptibility perturbations Magn Reson Med 34 555 566 10.1002/mrm.1910340412 8524024 1:STN:280:DyaK287gslKrsQ%3D%3D
45. MG Pomper JD Port 2000 New techniques in MR imaging of brain tumors Magn Reson Imaging Clin N Am 8 691 713 11175983 1:STN:280:DC%2BD3M7jslCisQ%3D%3D
46. MH Lev BR Rosen 1999 Clinical applications of intracranial perfusion MR imaging Neuroimaging Clin N Am 9 309 331 10318717 1:STN:280:DyaK1M3lt1aqug%3D%3D
47. JL Boxerman BR Rosen RM Weisskoff 1997 Signal-to-noise analysis of cerebral blood volume maps from dynamic NMR imaging studies J Magn Reson Imaging 7 528 537 10.1002/jmri.1880070313 9170038 1:STN:280:DyaK2szhtlKgtQ%3D%3D (Pubitemid 28360871)
48. O Thilmann EM Larsson IM Bjorkman-Burtscher F Stahlberg R Wirestam 2005 Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T J Magn Reson Imaging 22 597 604 10.1002/jmri.20420 16200539 (Pubitemid 41572711)
49. M Essig 2003 Clinical experience with MultiHance in CNS imaging Eur Radiol 13 Suppl 3 N3 10 10.1007/s00330-003-0001-5 15015875 (Pubitemid 38072465)
50. FL Giesel A Mehndiratta F Risse M Rius CM Zechmann H von Tengg-Kobligk L Gerigk HU Kauczor M Politi M Essig PD Griffiths ID Wilkinson 2009 Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla Acta Radiol 50 521 530 10.1080/02841850902787685 19337867
51. C Manka F Traber J Gieseke HH Schild CK Kuhl 2005 Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: feasibility and contrast agent dose Radiology 234 869 877 10.1148/radiol.2343040359 15665227 (Pubitemid 40250831)
52. C Catalano F Pediconi P Nardis A Roselli M Cavacece L Bertoletti R Passariello 2004 MR angiography with MultiHance for imaging the supra-aortic vessels Eur Radiol 14 Suppl 7 O45 O51 15503376
53. M Essig 2005 Gadobenate dimeglumine (MultiHance) in MR imaging of the CNS: studies to assess the benefits of a high relaxivity contrast agent Acad Radiol 12 Suppl 1 S23 S27 10.1016/j.acra.2005.02.020 16106542 (Pubitemid 41150890)
54. MV Knopp SO Schoenberg C Rehm F Floemer H von Tengg-Kobligk M Bock HR Hentrich 2002 Assessment of gadobenate dimeglumine for magnetic resonance angiography: phase I studies Invest Radiol 37 706 715 10.1097/00004424- 200212000-00011 12447005 1:CAS:528:DC%2BD38XovFShu7s%3D (Pubitemid 35429192)
55. F Pediconi F Fraioli C Catalano A Napoli M Danti M Francone F Venditti P Nardis R Passariello 2003 Gadobenate dimeglumine (Gd-DTPA) vs gadopentetate dimeglumine (Gd-BOPTA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio Radiol Med 106 87 93 12951555
56. E Bueltmann G Erb MA Kirchin U Klose T Naegele 2008 Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced magnetic resonance angiography of the supraaortic vessels at 3 Tesla Invest Radiol 43 695 702 10.1097/RLI.0b013e31817d1505 18791411 1:CAS:528:DC%2BD1cXhtFajt7nE
57. R Wyttenbach S Gianella M Alerci A Braghetti L Cozzi A Gallino 2003 Prospective blinded evaluation of Gd- Radiology 227 261 269 10.1148/radiol. 2271011989 12616007 (Pubitemid 36384208)
58. B Tombach W Heindel 2002 Value of 1.0-M gadolinium chelates: review of preclinical and clinical data on gadobutrol Eur Radiol 12 1550 1556 10.1007/s00330-001-1242-9 12042967 (Pubitemid 36940236)
59. M Goyen TC Lauenstein CU Herborn JF Debatin S Bosk SG Ruehm 2001 0.5 M Gd chelate (Magnevist) versus 1.0 M Gd chelate (Gadovist): dose-independent effect on image quality of pelvic three-dimensional MR-angiography J Magn Reson Imaging 14 602 607 10.1002/jmri.1225 11747013 1:STN:280:DC%2BD3MnpsFyksw%3D%3D (Pubitemid 33029547)
60. CU Herborn TC Lauenstein SG Ruehm S Bosk JF Debatin M Goyen 2003 Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography Invest Radiol 38 27 33 10.1097/00004424-200301000-00004 12496518 1:CAS:528:DC%2BD38Xps1Ohurw%3D (Pubitemid 36083433)
61. C Fink M Puderbach S Ley C Plathow M Bock I Zuna HU Kauczor 2004 Contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging: intraindividual comparison of 1.0 M gadobutrol and 0.5 M Gd-DTPA at three dose levels Invest Radiol 39 143 148 10.1097/01.rli.0000101482.79137.f4 15076006 (Pubitemid 38263920)
62. C Fink M Puderbach S Ley F Risse TA Kuder M Bock J Thaler C Plathow HU Kauczor 2005 Intraindividual comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine for time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the upper torso J Magn Reson Imaging 22 286 290 10.1002/jmri.20381 16028246 (Pubitemid 41045444)
63. H von Tengg-Kobligk F Floemer MV Knopp 2003 Multiphasic MR angiography as an intra-individual comparison between the contrast agents Gd-DTPA, Gd-BOPTA, and Gd-BT-DO3A Radiologe 43 171 178 10.1007/s00117-002-0857-4 (Pubitemid 36612279)
64. Q Dong DR Hurst HJ Weinmann TL Chenevert FJ Londy MR Prince 1998 Magnetic resonance angiography with gadomer-17 An animal study original investigation. Invest Radiol 33 699 708 1:STN:280:DyaK1cvjvFWqsA%3D%3D
65. B Tombach K Bohndorf W Brodtrager CD Claussen C Duber M Galanski E Grabbe G Gortenuti M Kuhn W Gross-Fengels R Hammerstingl B Happel G Heinz-Peer G Jung T Kittner R Lagalla P Lengsfeld R Loose RH Oyen P Pavlica C Pering R Pozzi-Mucelli T Persigehl P Reimer NS Renken GM Richter EJ Rummeny F Schafer M Szczerbo-Trojanowska A Urbanik TJ Vogl P Hajek 2008 Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial Eur Radiol 18 2610 2619 10.1007/s00330-008-1054-2 18607594
66. C Fink M Goyen J Lotz 2007 Magnetic resonance angiography with blood-pool contrast agents: future applications Eur Radiol 17 Suppl 2 B38 B44 17650559
67. M Essig K Nikolaou JF Meaney 2007 Magnetic resonance angiography of the head and neck vessels Eur Radiol 17 Suppl 2 B30 B37 17650558
68. JF Meaney M Goyen 2007 Recent advances in contrast-enhanced magnetic resonance angiography Eur Radiol 17 Suppl 2 B2 B6 17650553
69. C Reisinger T Gluecker AL Jacob G Bongartz D Bilecen 2009 Dynamic magnetic resonance angiography of the arteries of the hand A comparison between an extracellular and an intravascular contrast agent. Eur Radiol 19 495 502
70. C Klessen PA Hein A Huppertz M Voth M Wagner T Elgeti H Kroll B Hamm M Taupitz P Asbach 2007 First-pass whole-body magnetic resonance angiography (MRA) using the blood-pool contrast medium gadofosveset trisodium: comparison to gadopentetate dimeglumine Invest Radiol 42 659 664 10.1097/RLI.0b013e318063c635 17700282 (Pubitemid 47262935)
71. R Iezzi G Soulez S Thurnher G Schneider MA Kirchin N Shen G Pirovano A Spinazzi 2009 Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: Comparison of gadobenate dimeglumine and gadofosveset trisodium Eur J Radiol 10.1016/j.ejrad.2009.07.020
72. ME Moseley J Kucharczyk J Mintorovitch Y Cohen J Kurhanewicz N Derugin H Asgari D Norman 1990 Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats AJNR Am J Neuroradiol 11 423 429 2161612 1:STN:280:DyaK3c3ntl2jsA%3D%3D
73. S Warach J Gaa B Siewert P Wielopolski RR Edelman 1995 Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging Ann Neurol 37 231 241 10.1002/ana.410370214 7847864 1:STN:280: DyaK2M7ltVGnsQ%3D%3D
74. Y Ge 2006 Multiple sclerosis: the role of MR imaging AJNR Am J Neuroradiol 27 1165 1176 16775258 1:STN:280:DC%2BD28zmtVajtw%3D%3D
75. J Theberge 2008 Perfusion magnetic resonance imaging in psychiatry Top Magn Reson Imaging 19 111 130 10.1097/RMR.0b013e3181808140 19363433
76. P Caravan CT Farrar L Frullano R Uppal 2009 Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium-and manganese-based T1 contrast agents Contrast Media Mol Imaging 4 89 100 10.1002/cmmi.267 19177472 1:CAS:528:DC%2BD1MXltlahtbY%3D
77. P Fries VM Runge A Bucker H Schurholz W Reith P Robert C Jackson T Lanz G Schneider 2009 Brain tumor enhancement in magnetic resonance imaging at 3 Tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular Gd-chelate in a rat brain tumor model Invest Radiol 44 200 206 10.1097/RLI.0b013e31819817ff 19300099
78. P Caravan 2009 Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action Acc Chem Res 42 851 862 10.1021/ar800220p 19222207 1:CAS:528:DC%2BD1MXhvFGgtLs%3D
79. T Barrett M Brechbiel M Bernardo PL Choyke 2007 MRI of tumor angiogenesis J Magn Reson Imaging 26 235 249 10.1002/jmri.20991 17623889 (Pubitemid 47257720)